Grace Therapeutics (GRCE) Accumulated Expenses (2017 - 2026)
Grace Therapeutics (GRCE) posted Accumulated Expenses of $719000.0 for Q1 2026, up 30.73% sequentially from $550000.0 in Q4 2025, and up 8.77% YoY from $661000.0 in Q1 2025.
Grace Therapeutics (GRCE) Accumulated Expenses (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Accumulated Expenses for 10 years, with the latest figure at $719000.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 8.77% year-over-year to $719000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $719000.0 (up 8.77% YoY) and the FY2026 annual result came in at $719000.0, up 8.77% from the prior year.
- Accumulated Expenses advanced to $719000.0 in Q1 2026 per GRCE's latest filing, from $550000.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.2 million in Q1 2022 and troughed at $237000.0 in Q2 2024.
- A 5-year average of $611714.3 and a median of $516500.0 in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 53.31% in 2022, then slumped 76.16% in 2024.
- Over 5 years, Accumulated Expenses stood at $1.2 million in 2022, then slumped by 54.99% to $532000.0 in 2023, then slipped by 7.52% to $492000.0 in 2024, then advanced by 11.79% to $550000.0 in 2025, then surged by 30.73% to $719000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $719000.0, $550000.0, and $412000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 419,000.00 |
| Mar 31, 2026 | 719,000.00 |
| Dec 31, 2025 | 550,000.00 |
| Sep 30, 2025 | 412,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 661,000.00 |
| Dec 31, 2024 | 492,000.00 |
| Sep 30, 2024 | 373,000.00 |
| Jun 30, 2024 | 237,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Dec 31, 2023 | 532,000.00 |
| Sep 30, 2023 | 460,000.00 |
| Jun 30, 2023 | 994,000.00 |
| Mar 31, 2023 | 1.15 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Mar 31, 2021 | 771,000.00 |
| Mar 31, 2020 | 4.25 Mn |
| Mar 31, 2019 | 792,544.04 |
| Mar 31, 2018 | 1.96 Mn |
| Feb 28, 2017 | 365,660.84 |